Med-Tech Innovation January 31, 2024

Carcinotech has raised $5.3 million of funding as the company looks to build on its traction in the UK and Europe, with US expansion planned later this year.

Carcinotech’s Carcino3D technology enables the manufacture of 3D printed micro-tumours, using cells derived from patient biopsies and blood samples to simulate the tumour microenvironment, accelerating ethical drug screening and the delivery of more effective cancer treatments to market.

Ishani Malhotra, CEO and founder of Carcinotech, said: “Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: 3D Printing, Investments, Technology, Trends
How 3D Printing Impacts Radiology
Ricoh’s 3D Printing Improves Surgical Accuracy and Safety One Layer at a Time
3D-printed hydrogel enables continuous drug delivery via contact lens
Improved 3D printed blood vessels thanks to bioink with DNA
DNA-based bioink technology enables precise 3D-printing of blood vessels

Share This Article